The world domination plans of drug giant Novo Nordisk have hit a bump in the road. The Danish company became one of the world’s fastest-growing corporations after releasing its weight-loss drug sensation, Wegovy—but the results from trials of its next-generation obesity therapy, CagriSema, have been disappointing.
The news wiped $125 billion from the value of the company in a single day, making it one of the biggest ever one-day wipeouts on stock markets.